SURMOUNT-4 looked at weight maintenance
Lancet Diabetes Endocrinol 9:653662
If your vial or pen touches this surface, it can partially freeze
The initial dosing starts at 0.25 mg per week and is gradually increased at 4-week intervals to 0.5, 1.0, 1.7 mg, and finally to a maximum dose of 2.4 mg per week
As of January 6, 2025 here is a list of approved and pending new GLP-1 agonists class of medications that can help manage Type 2 diabetes and obesity: Ozempic (semaglutide) Approved - A weekly injectable GLP-1 receptor agonist that helps regulate blood sugar and suppress appetite, promoting weight loss in addition to managing type 2 diabetes
Some users experience mild return of appetite during this gap, which confirms the medications were working and resolves once the new medication takes effect